1. Home
  2. PML vs RCEL Comparison

PML vs RCEL Comparison

Compare PML & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Municipal Income Fund II of Beneficial Interest

PML

Pimco Municipal Income Fund II of Beneficial Interest

N/A

Current Price

$6.96

Market Cap

445.5M

Sector

Finance

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

N/A

Current Price

$15.68

Market Cap

403.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PML
RCEL
Founded
2002
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
445.5M
403.3M
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
PML
RCEL
Price
$6.96
$15.68
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $13.57
AVG Volume (30 Days)
★ 1.0M
393.1K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 5.65%
N/A
EPS Growth
N/A
★ 27.20
EPS
★ N/A
N/A
Revenue
N/A
★ $71,610,000.00
Revenue This Year
N/A
$23.78
Revenue Next Year
N/A
$26.87
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 11.45
52 Week Low
$6.39
$3.22
52 Week High
$7.96
$16.90

Technical Indicators

Market Signals
Indicator
PML
RCEL
Relative Strength Index (RSI) 62.42 65.27
Support Level $6.39 $3.86
Resistance Level $7.66 N/A
Average True Range (ATR) 0.10 0.86
MACD 0.05 0.12
Stochastic Oscillator 91.67 68.33

Price Performance

Historical Comparison
PML
RCEL

About PML Pimco Municipal Income Fund II of Beneficial Interest

PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: